A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. G. Corrie*, P. Terheyden, A. J. ten Tije, R. Herbst, R. Jansen, M. Marples, D. Debus, R. Marconcini, M. Blasinska-Morawiec, K. Freivogel, M. L. G. Munson, G. R. Goodman, J. J. Hsu, N. Sadetsky, D. Colburn, P. Rutkowski

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1254-1255
Number of pages2
JournalBritish Journal of Dermatology
Volume180
Issue number5
DOIs
Publication statusPublished - May 2019

Keywords

  • COBIMETINIB
  • SURVIVAL

Cite this

Corrie, P. G., Terheyden, P., ten Tije, A. J., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska-Morawiec, M., Freivogel, K., Munson, M. L. G., Goodman, G. R., Hsu, J. J., Sadetsky, N., Colburn, D., & Rutkowski, P. (2019). A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British Journal of Dermatology, 180(5), 1254-1255. https://doi.org/10.1111/bjd.17465